Jürgen Braunger

Title: Jürgen Braunger: Innovator in Kinesin Modulation

Introduction

Jürgen Braunger is a notable inventor based in Constance, Germany. He has made significant contributions to the field of kinesin modulation, particularly through his innovative compounds that exhibit anti-proliferative and apoptosis-inducing activities. With a total of 2 patents to his name, Braunger continues to push the boundaries of scientific research.

Latest Patents

Braunger's latest patents include groundbreaking work on indolopyridines and benzothienopyridines. The first patent focuses on indolopyridines as Eg5 kinesin modulators, detailing compounds of a specific formula that demonstrate effective anti-proliferative and apoptosis-inducing activity. The second patent involves benzothienopyridines, which are described as novel effective compounds with Eg5 inhibitory properties, also showcasing anti-proliferative and apoptosis-inducing activities.

Career Highlights

Jürgen Braunger is currently associated with 4SC AG, a company dedicated to developing innovative therapies for cancer and autoimmune diseases. His work at 4SC AG has allowed him to collaborate with other talented professionals in the field, further enhancing his contributions to scientific research.

Collaborations

Braunger has worked alongside notable colleagues such as Matthias Vennemann and Thomas Baer. Their collaborative efforts have played a crucial role in advancing the research and development of new therapeutic compounds.

Conclusion

Jürgen Braunger's innovative work in kinesin modulation has positioned him as a key figure in the field of medicinal chemistry. His patents reflect a commitment to developing effective treatments that could significantly impact cancer therapy.